Navigation Links
FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
Date:3/19/2008

BOSTON, March 19 /PRNewswire/ -- FluoroPharma Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced commencement of Phase I clinical trials for BFPET, following institutional review board (IRB) approval of the proposed studies. The Phase I trial is a single center, open label study, designed to evaluate safety, distribution and dosimetry of BFPET as a PET tracer for myocardial perfusion imaging in healthy subjects. The study will be led by Dr. Alan Fischman, Professor of Radiology at Harvard Medical School and former Director of the Nuclear Medicine Division at Massachusetts General Hospital. BFPET is FluoroPharma's second cardiovascular PET agent to enter clinical trials.

BFPET is a PET blood flow imaging agent, for use in classic "rest-stress" cardiac testing. More than 9 million Americans each year undergo myocardial perfusion imaging, the standard test to assess coronary artery disease (CAD). BFPET, as a PET imaging tracer, may have a significant advantage due to its potential to improve the sensitivity and specificity of CAD diagnosis and to provide information on myocardial mitochondrial damage. "This agent, if successful, should improve CAD diagnosis and follow-up of therapy and intervention, and broaden the utility of PET as an imaging modality," said Dr. David Elmaleh, FluoroPharma's Chairman and Scientific Founder. "BFPET has performed well in animals with a target-to-blood ratio of 70:1, and we look forward to evaluating the agent in human studies."

"We are delighted to have our second product enter clinical trials," said Dr. Ljiljana Kundakovic, FluoroPharma's President. "BFPET's progress follows on the tail of CardioPET, an agent for the detection of metabolic integrity of the heart, which recently completed a Phase I safety evaluation in normal healthy volunteers and cardiac patients. FluoroPharma has the potential to significantly impact diagnos
'/>"/>

SOURCE FluoroPharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
2. Emisphere Announces Second Study Demonstrating Dramatic Increases in Absorption of Oral B12 Using eligen(R) Technology at Lower Doses
3. Poniard Pharmaceuticals Announces Clinical Data From Picoplatin Oral Phase 1 to Be Presented at the American Association of Cancer Research Annual Meeting
4. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
5. Micromet Announces Presentation of Five Posters Related to Its Proprietary BiTE Antibody Platform at Annual Meeting of American Association for Cancer Research
6. Nuvelo Announces Phase 2 SONOMA-3 Trial Did Not Meet Target Product Profile and Discontinues Alfimeprase Development
7. MacroChem Announces Presentation of Pexiganan Phase 3 Study Results for Topical Treatment of Diabetic Foot Infection
8. Synbiotics Corporation Announces Human Submission for FluDetect(R)
9. Raven Announces Initiation of a RAV12 Phase 2 Clinical Trial in Metastatic Pancreatic Cancer
10. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
11. Progen Announces Commencement of Global Phase 3 Study for PI-88 in Post- Resection Liver Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... Nov. 24, 2014  Surgical Theater, LLC, announced today ... 24 th opening of Europe,s ... Nazionale "C. Besta." The SuRgical Planner (SRP) and the ... the event for their 3D navigation and augmented reality ... Bederson , Professor and Chair, Department of Neurosurgery at ...
(Date:11/24/2014)... 24, 2014  Pifflers United Chronic and Invisible ... release of results of a study of ActiPatch®, ... self-management of fibromyalgia pain. The results demonstrated that ... very significant clinically meaningful pain reduction can be ... with fibromyalgia used ActiPatch® for 7 days and ...
(Date:11/22/2014)...  Sprout Pharmaceuticals today announced positive preliminary results from a ... flibanserin up to 200 mg at bedtime had no next-day ... 20 th Annual Fall Scientific Meeting of the Sexual ... Miami . The Phase 1 ... Letter and the Formal Dispute Resolution that was filed in ...
Breaking Medicine Technology:Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3
(Date:11/24/2014)... The Holiday Inn Westbury - Long Island ... Association to donate various items consisting of practical, ... such items.The Association's program is aimed toward helping over ... nursing homes, assisted living facilities and nursing homes. The ... of seniors throughout the Long Island area. The Holiday ...
(Date:11/24/2014)... and Philadelphia, PA (PRWEB) November 24, 2014 ... of care coordination and disease management services to ... chosen to implement Essetteā€™s Medical Management software suite. ... Essette SaaS platform in a program to reduce ... suite includes Population Health Management, Care Management, Utilization ...
(Date:11/23/2014)... iFitDress.com, a well-known wedding dress manufacturer, has unveiled its ... They are now offered at deeply discounted prices, up to ... to Dec. 15. The main purpose of the promotion is ... quality items are ideal options for ladies who are eager ... All its new mint cocktail dresses are very beautiful; they ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Nearly ... heart attacks, strokes, deep vein thrombosis and other ... a federal multidistrict litigation (MDL) underway in the ... , Court documents updated on November 17th ... (JPML) show the filing of 259 lawsuits against ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 To show thanks ... its new collection of white evening dresses for ... online workers 24/7. , iFitDress.com is a distinguished dress manufacturer, ... and supported by worldwide customers for a very long time. ... place where a customer will be able to buy not ...
Breaking Medicine News(10 mins):Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
... Tobacco-Free,Kids, WASHINGTON, Oct. 2 The following is ... Kids:, The Campaign for Tobacco-Free Kids applauds Tyra ... exposing the ugly truth that,smoking is not only dangerous ... week,s season premiere of "America,s Next Top Model",featured a ...
... Manchester scientists will discuss their research aimed at reducing ... at the National Cancer Research Institute conference in Birmingham ... patients receive radiotherapy as part of their cancer treatment ... causing side effects (toxicity) to the normal tissues and ...
... For the first time, data show a positive ... overall health at birth. Babies born to women with ... to be less likely to need intensive care than ... Inc. (NASDAQ:CBRX) announced today. The data are published in ...
... Angel Flight West (AFW),awarded The Distinguished Pilot award ... Awards on Saturday, September 29. Dr. Irish,completed 18 Angel ... AFW,pilot, he flies people in need whose non-emergency health ... facilities. Dr. Irish, like,all AFW volunteer pilots, donates the ...
... Does your October purchase really make a difference?, ... products to,benefit the breast cancer cause, Y-ME National Breast ... make meaningful,consumer choices to ensure that their money really ... consumers can take to become informed about,pink, promotions so ...
... HILL, N.C., Oct. 2 The U.S. hospital ... vying to get their,therapies on hospital formularies. Among ... time with key physicians and the list of ... companies are working their way into formularies via,specialized ...
Cached Medicine News:Health News:Tobacco-Free Kids Applauds Tyra Banks for Exposing the Ugly Truth About Smoking 2Health News:Cancer researchers seek safe reduction of radiotherapy 2Health News:Vaginal progesterone gel may improve infant outcomes and... 2Health News:Vaginal progesterone gel may improve infant outcomes and... 3Health News:Vaginal progesterone gel may improve infant outcomes and... 4Health News:Angel Flight West Recognizes Colorado Pilots and Supporters at AFW 24th Anniversary Awards 2Health News:National Breast Cancer Awareness Month 2Health News:Equipping your Sales Force to Influence Hospital Formulary Decision-Makers 2
... Chrono-log's wide range of Platelet aggregometers ... to meet particular needs. Single, dual ... with chart recorder outputs or digital ... Chrono-log Optical aggregometers, which measure platelet ...
... a four channel platelet aggregation profiler combined ... in conjunction with Microsoft WindowsTM, the PAP-4CD ... tests, automatic storage of test results, plus ... test modes are available: chromogenic assays, von ...
... is a four channel platelet aggregation profiler ... assays, von Willebrand assay (Ristocetin cofactor), platelet ... also be used for the evaluation and ... channels allow four tests to be run ...
... plus, innovation means 4 on-board measurement ... and im-proved operator ergonomics. This supports ... required for true workload consolidation, leading ... only one analytical platform, one user ...
Medicine Products: